Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol

Lancet

Volumn 359, Issue 9311, 2002, Pages 995-1003

  Dahlöf, Björn ^a   Devereux, Richard B ^b   Kjeldsen, Sverre E ^c   Julius, Stevo ^d   Beevers, Gareth ^e   De Faire, Ulf ^f   Fyhrquist, Frej ^g   Ibsen, Hans ^h   Kristiansson, Krister ⁱ   Lederballe Pedersen, Ole ^j   Lindholm, Lars H ^k   Nieminen, Markku S ^g   Omvik, Per ^l   Oparil, Suzanne ^m   Wedel, Hans ⁿ  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF MICHIGAN   (United States)

^e CITY HOSPITAL   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

ⁱ Merck Research Laboratories Scandinavia   (Sweden)

^j VIBORG HOSPITAL   (Denmark)

^k UMEÅ UNIVERSITY   (Sweden)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE; BRADYCARDIA; CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLD LIMB; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DYSPNEA; EDEMA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEXUAL DYSFUNCTION; SLEEP DISORDER; STROKE; THORAX PAIN; TREATMENT OUTCOME; VERTIGO;

EID: 0037160968     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08089-3     Document Type: Article

References (30)

1. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
2. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: Rationale, design, and methods
3. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
4. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease
5. Reversal of left ventricular hypertrophy in hypertensive patients - A meta-analysis of 109 treatment studies
6. Left ventricular hypertrophy and angiotensin II antagonists
7. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
8. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
9. Angiotensin II receptor antagonists: An emerging new class of cardiovascular therapeutics
10. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
11. Pharmacotherapy for hypertension in the elderly (Cochrane review)
12. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
13. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1
14. Characteristics of 9,194 patients with left ventricular hypertrophy: The LIFE study
15. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study
16. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products
17. Electrocardiographic identification of left ventricular hypertrophy: Test performance in relation to definition of hypertrophy and presence of obesity
18. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer electrocardiogram interpretation: Necropsy validation
19. Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: Results of a correlated data base approach
20. Improved electrocardiographic diagnosis of left ventricular hypertrophy
21. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study
22. An updated coronary risk profile: A statement for health professionals
23. Stroke is more common than myocardial infarction in hypertension: Analysis based on 11 major randomised intervention trials
24. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension
25. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
26. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials
27. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
28. Regression of left ventricular hypertrophy as a surrogate endpoint for morbid events in hypertension treatment trials
29. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy